CorMedix (CRMD) Expected to Announce Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of $0.8160 per share and revenue of $127.0190 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, March 5th. The company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.70). CorMedix had a net margin of 52.31% and a return on equity of 52.30%. The business had revenue of $128.62 million for the quarter, compared to analysts’ expectations of $127.02 million. During the same period in the prior year, the company posted $0.22 earnings per share. The firm’s quarterly revenue was up 312.1% on a year-over-year basis. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

CorMedix Stock Up 2.7%

CRMD opened at $6.42 on Tuesday. The firm’s 50 day simple moving average is $7.12 and its two-hundred day simple moving average is $9.73. The company has a market capitalization of $507.50 million, a PE ratio of 3.21 and a beta of 1.31. CorMedix has a 1-year low of $5.60 and a 1-year high of $17.43. The company has a current ratio of 2.11, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36.

CorMedix announced that its board has approved a stock repurchase program on Monday, February 2nd that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 12.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages recently commented on CRMD. Needham & Company LLC decreased their target price on CorMedix from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Zacks Research lowered CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. HC Wainwright cut their price objective on CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, Leerink Partners reissued an “outperform” rating and issued a $13.00 target price on shares of CorMedix in a report on Friday, March 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CorMedix currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Insider Buying and Selling

In other CorMedix news, Director Alan W. Dunton sold 20,000 shares of the stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total transaction of $260,000.00. Following the completion of the transaction, the director owned 40,250 shares of the company’s stock, valued at $523,250. This represents a 33.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CorMedix

A number of hedge funds have recently made changes to their positions in the company. State of Tennessee Department of Treasury bought a new position in CorMedix during the fourth quarter valued at approximately $223,000. Empowered Funds LLC bought a new stake in CorMedix in the 4th quarter worth approximately $1,534,000. VARCOV Co. bought a new stake in CorMedix in the 4th quarter worth approximately $1,987,000. Inspire Investing LLC purchased a new stake in shares of CorMedix during the 4th quarter worth approximately $1,247,000. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of CorMedix by 105.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 43,431 shares of the company’s stock worth $505,000 after acquiring an additional 22,283 shares in the last quarter. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.